DIASTOLIC FUNCTION IN MYOSIN-BINDING PROTEIN C FOUNDER MUTATION CARRIERS WITH AND WITHOUT CLINICAL EVIDENCE OF HYPERTROPHIC CARDIOMYOPATHY

The MYBPC3 (Myosin-binding protein C) c.927-2A>G founder mutation accounts for >90% of sarcomeric hypertrophic cardiomyopathy (HCM) in Iceland, allowing unique opportunity to explore the relation between genotype and clinical phenotype. This study explores the burden of diastolic dysfunction in a